{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:19:36Z","timestamp":1760782776121},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s10637-005-2905-1","type":"journal-article","created":{"date-parts":[[2005,8,13]],"date-time":"2005-08-13T20:13:36Z","timestamp":1123964016000},"page":"455-465","source":"Crossref","is-referenced-by-count":3,"title":["Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies"],"prefix":"10.1007","volume":"23","author":[{"given":"Eric X.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Batist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeema","family":"Bangash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Maclean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Lathia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Petrenciuc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2905_CR1","first-page":"641","volume":"8","author":"R Garcia-Carbonero","year":"2002","unstructured":"Garcia-Carbonero R, Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8: 641\u2013661, 2002","journal-title":"Clin Cancer Res"},{"key":"2905_CR2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","volume":"85","author":"WJ Slichenmyer","year":"1993","unstructured":"Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271\u2013291, 1993","journal-title":"J Natl Cancer Inst"},{"key":"2905_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905\u2013914, 2000","journal-title":"Irinotecan Study Group. N Engl J Med"},{"key":"2905_CR4","first-page":"2182","volume":"7","author":"RH Mathijssen","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182\u20132194, 2001","journal-title":"Clin Cancer Res"},{"key":"2905_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85\u201391, 2002","journal-title":"N Engl J Med"},{"key":"2905_CR6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","volume":"17","author":"J von Pawel","year":"1999","unstructured":"von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658\u2013667, 1999","journal-title":"J Clin Oncol"},{"key":"2905_CR7","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","volume":"15","author":"HW ten Bokkel","year":"1997","unstructured":"ten Bokkel HW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183\u20132193, 1997","journal-title":"J Clin Oncol"},{"key":"2905_CR8","first-page":"104","volume":"23","author":"MF Fung","year":"2002","unstructured":"Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B: Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum\u2013a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol 23: 104\u2013110, 2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"2905_CR9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jps.2600840426","volume":"84","author":"TG Burke","year":"1995","unstructured":"Burke TG, Munshi CB, Mi Z, Jiang Y: The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84: 518\u2013519, 1995","journal-title":"J Pharm Sci"},{"key":"2905_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1006\/abio.1993.1325","volume":"212","author":"TG Burke","year":"1993","unstructured":"Burke TG, Mi Z: Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212: 285\u2013287, 1993","journal-title":"Anal Biochem"},{"key":"2905_CR11","doi-asserted-by":"publisher","first-page":"12540","DOI":"10.1021\/bi00208a002","volume":"33","author":"Z Mi","year":"1994","unstructured":"Mi Z, Burke TG: Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study. Biochemistry 33: 12540\u201312545, 1994","journal-title":"Biochemistry"},{"key":"2905_CR12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.1998.16.3.1122","volume":"16","author":"LL Siu","year":"1998","unstructured":"Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16: 1122\u20131130, 1998","journal-title":"J Clin Oncol"},{"key":"2905_CR13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1749-6632.1996.tb26392.x","volume":"803","author":"EA Natelson","year":"1996","unstructured":"Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224\u2013230, 1996","journal-title":"Ann NY Acad Sci"},{"key":"2905_CR14","first-page":"2134","volume":"8","author":"FJ Giles","year":"2002","unstructured":"Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM: Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 8: 2134\u20132141, 2002","journal-title":"Clin Cancer Res"},{"key":"2905_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00280-002-0463-1","volume":"50","author":"T Minko","year":"2002","unstructured":"Minko T, Paranjpe PV, Qiu B, Lalloo A, Won R, Stein S, Sinko PJ: Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 50: 143\u2013150, 2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"2905_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2003.03.143","volume":"21","author":"EK Rowinsky","year":"2003","unstructured":"Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, Hammond LA, Patnaik A, Kwiatek J, Goetz A, Denis L, McGuire J, Tolcher AW: A phase I and pharmacokinetic study of pegylated camptothecin as a 1\u2013hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 21: 148\u2013157, 2003","journal-title":"J Clin Oncol"},{"key":"2905_CR17","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1021\/jm010893l","volume":"44","author":"HG Lerchen","year":"2001","unstructured":"Lerchen HG, Baumgarten J, von dem BK, Lehmann TE, Sperzel M, Kempka G, Fiebig HH: Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 44: 4186\u20134195, 2001","journal-title":"J Med Chem"},{"key":"2905_CR18","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1002\/(SICI)1521-3773(19991216)38:24<3680::AID-ANIE3680>3.0.CO;2-9","volume":"38","author":"HG Lerchen","year":"1999","unstructured":"Lerchen HG, Baumgarten J, Piel N, Kolb-Bachofen V: Lectin-mediated drug targeting: discrimination of carbohydrate-mediated cellular uptake between tumor and liver cells with neoglycoconjugates carrying fucose epitopes regioselectively modified in the 3-position. Angew Chem Int Ed Engl 38: 3680\u20133683, 1999","journal-title":"Angew Chem Int Ed Engl"},{"key":"2905_CR19","first-page":"538","volume":"41","author":"G Clemens","year":"2000","unstructured":"Clemens G, Lebel E, Hartnagel RE, Schmidt U, von Keutz E, Schluter G, Kayser M, Achterrath W: An intravenous infusion toxicology program with Bay 38-3441 in the mouse, rat and dog (Abstract). Proc Am Assoc Cancer Res 41: 538, 2000 (abstr 3430)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2905_CR20","first-page":"537","volume":"41","author":"E Lebel","year":"2000","unstructured":"Lebel E, Clemens G, Hartnagel RE, Tellier P, and Schmidt U: An intravenous infusion toxicity study comparing the toxicity of Bay 38-3441 with topotecan in the beagle dog (Abstract). Proc Am Assoc Cancer Res 41: 537, 2000 (abstr 3426)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2905_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216, 2000","journal-title":"J Natl Cancer Inst"},{"key":"2905_CR22","first-page":"538","volume":"42","author":"V Agarwal","year":"2001","unstructured":"Agarwal V, Lathia C, Wu Y, and Schwartz G. High performance liquid chromatographic-electrospray tandem mass spectrometry procedure for simulaneous quantitation of a camptothecin glycoconjugate, Bay 38-3441, and its lactone metabolite in blood and plasma for pharmacokinetic evaluation during a phase I study (Abstract). Proc Am Assoc Cancer Res 42: 538, 2001 (abstr 2898)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2905_CR23","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2001.19.18.3801","volume":"19","author":"ML Rothenbergc","year":"2001","unstructured":"Rothenbergc ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil\/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801\u20133807, 2001","journal-title":"J Clin Oncol"},{"key":"2905_CR24","first-page":"461","volume":"54","author":"JA Gottlieb","year":"1970","unstructured":"Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461\u2013470, 1970","journal-title":"Cancer Chemother Rep"},{"key":"2905_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1349-7006.1995.tb02995.x","volume":"86","author":"Y Sasaki","year":"1995","unstructured":"Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K: Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86: 111\u2013116, 1995","journal-title":"Jpn J Cancer Res"},{"key":"2905_CR26","first-page":"427","volume":"54","author":"EK Rowinsky","year":"1994","unstructured":"Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427\u2013436, 1994","journal-title":"Cancer Res"},{"key":"2905_CR27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bjc.1996.243","volume":"73","author":"JH Schellens","year":"1996","unstructured":"Schellens JH, Creemers GJ, Beijnen JH, Rosing H, Boer-Dennert M, McDonald M, Davies B, Verweij J: Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br J Cancer 73: 1268\u20131271, 1996","journal-title":"Br J Cancer"},{"key":"2905_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/annonc\/mdh313","volume":"15","author":"K Mross","year":"2004","unstructured":"Mross K, Richly H, Schleucher N, Korfee S, Tewes M, Scheulen ME, Seeber S, Beinert T, Schweigert M, Sauer U, Unger C, Behringer D, Brendel E, Haase CG, Voliotis D, Strumberg D: A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. Ann Oncol 15: 1284\u20131294, 2004","journal-title":"Ann Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-2905-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-005-2905-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-2905-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-2905-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:02:01Z","timestamp":1678557721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-005-2905-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["2905"],"URL":"https:\/\/doi.org\/10.1007\/s10637-005-2905-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}